Category Archives: – NEJM

Triple Therapy for Cystic Fibrosis

October 18, 2018- interviewed by Steven E. Greer, MD

Posted in - Biotech, - NEJM, - Pharma, FDA, Genetics, Infectious disease, Internal Medicine, National Jewish Health, Pediatrics, Pulmonology | Leave a comment

Crystalloid “Balanced Lactated Ringer’s” IV solution is safer to the kidneys

March 1, 2018- Interviewed by Steven E. Greer, MD We interviewed Vanderbilt’s Todd Rice, MD about his NEJM papers that showed crystalloid, or

Posted in - NEJM, Cardiac surgery, Cardiology, Emergency medicine, General surgery, Internal Medicine, Neurology, Neurosurgery, Obstetrics and Gynecology, Oncology, Orthopedic surgery, Pediatrics, Plastic surgery, Sports medicine, Trauma Surgery, Urology, Vanderbilt, Vascular Surgery | Leave a comment

Does President Trump have “heart disease” based on his Coronary Calcium Score?

January 20, 2018- by Steven E. Greer, MD President Trump made news this week by having his doctor, Admiral Ronny Jackson, MD, answer

Posted in - NEJM, - Opinion, - Policy, Cardiac surgery, Cardiology, CDC, Emory, Internal Medicine, Neurosurgery, NIH | Leave a comment

The new CDC guidelines for prescribing opioid pain pills

June 1, 2016- Interviewed by Steven E. Greer, MD Pain pill prescriptions have quadrupled since the 1990’s as drug companies stepped up marketing and funded

Posted in - JAMA, - NEJM, - Pharma, CDC, Emergency medicine, General surgery, Oncology, Psychology Psychiatry, Rehab, Spine surgery, Sports medicine | Leave a comment

Effects of Spaceflight on Astronaut Brain Structure as Indicated on MRI

November 22, 2017 – Interviewed by Steven E. Greer, MD We interviewed Donna Roberts, MD of the Medical University of South Carolina about her NEJM paper

Posted in - NEJM, Medical University of South Carolina, Neurology, Neurosurgery, Ophthalmology, Radiology | Leave a comment

Once again, daily aspirin is shown to be deadly rather than beneficial

September 16, 2018- by Steven E. Greer, MD The Healthcare Channel has been pounding the table for many years pushing back against the drug

Posted in - NEJM, - Pharma, Cardiac surgery, Cardiology, Gastroenterology and liver, Geriatrics, Internal Medicine, Neurology, Neurosurgery, Oncology, Vascular Surgery | Leave a comment

Is Vitamin-D deficiency overdiagnosed?

November 8, 2016- Interviewed by Steven E. Greer, MD We interviewed JoAnn E. Manson, MD, DrPH, Chief, Division of Preventive Medicine,  Brigham

Posted in - NEJM, - Policy, CDC, Diabetes and endocrinology, FDA, Harvard, Primary care medicine | Leave a comment

KIT inhibition by Gleevec (imatinib) for severe asthma

May 26, 2017- Interviewed by Steven E. Greer, MD Novartis’ Gleevec (imatinib) was approved in the U.S. in 2001 to treat leukemia. Now, researchers

Posted in - Biotech, - NEJM, - Pharma, National Jewish Health, Pulmonology | Leave a comment

Told you so: the NEJM Mediterranean diet was junk science

June 13, 2018- by Steven E. Greer, MD Back in 2013, I pounded the

Posted in - NEJM, - Opinion, Cardiology, Primary care medicine | Leave a comment

Mechanical heart valves provide much lower mortality than tissue valves in young patients

November 8, 2017- by Steven E. Greer, MD Off the radar of Wall Street analysts is a new paper in the NEJM that shows mechanical heart valves, both aortic and mitral, impart much lower mortality than tissue valves in the … Continue reading

Posted in - Medical Devices, - NEJM, Cardiac surgery, Cardiology | Leave a comment

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

February 27, 2017- interviewed by Steven E. Greer, MD We interviewed Joaquim Bellmunt, MD, PhD, the Director of the Bladder Cancer Center at Dana-Farber,

Posted in - Biotech, - NEJM, - Pharma, Harvard, Oncology | Leave a comment

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer (FLAURA)

November 20, 2017- Interviewed by Steven E. Greer, MD We interviewed Emory University oncologist Suresh S. Ramalingam, M.D. about his NEJM

Posted in - NEJM, Cardiac surgery, Emory, Oncology | Leave a comment

Ocrelizumab (Ocrevus) versus Placebo in Primary Progressive Multiple Sclerosis

January 31, 2017- Interviewed by Steven E. Greer, MD

Posted in - Biotech, - NEJM, - Pharma, Neurology, Univ Texas | 1 Comment

CT-scan screening for heart disease fails to show benefit

March 23, 2015- Interviewed by Steven E. Greer, MD We interviewed the Principal Investigator of the PROMISE trial, Pamela Douglas, MD from Duke.

Posted in - NEJM, - Policy, Cardiology, CMS, Duke, Radiology | Leave a comment

Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis

May 23, 2017- interviewed by Steven E. Greer, MD We interviewed polumonologist Michael Wechsler, MD about his paper in the NEJM testing mepolizumab

Posted in - NEJM, National Jewish Health, Pulmonology, Rheumatology | Leave a comment

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors

January 12, 2017- Interviewed by Steven E. Greer, MD Jonathan Strosberg, MD of

Posted in - NEJM, Oncology | Leave a comment

The bionic pancreas data

July 2, 2014- Interviewed by Steven E. Greer, MD The New England Journal of Medicine recently published the early clinical data on the “bionic pancreas”

Posted in - Medical Devices, - NEJM, Boston University, Diabetes and endocrinology | Leave a comment

Aerobic or Resistance Exercise, or Both, in Dieting Obese Older Adults

June 14, 2017- Interviewed by Steven E. Greer, MD We interviewed Dennis Villareal, MD, the author of the NEJM paper “Aerobic or Resistance

Posted in - NEJM, Bariatric surgery, Baylor, Diabetes and endocrinology, Geriatrics, Internal Medicine | Leave a comment

The ACA’s THC program: A pilot program to fund residency training outside of the traditional hospital setting

September 6, 2016- Interviewed by Steven E. Greer, MD

Posted in - NEJM, - Policy, CMS, George Washington Univ | Leave a comment

Ibrance (palbociclib) to treat advanced breast cancer

November 28, 2016- Interviewed by Steven E. Greer, MD We interviewed Richard Finn,

Posted in - Biotech, - NEJM, - Pharma, Oncology, UCLA | Leave a comment